<DOC>
	<DOCNO>NCT00000682</DOCNO>
	<brief_summary>To evaluate efficacy AZT versus ddC term survival , antiviral effect , neurological status , health status patient post Pneumocystis carinii pneumonia ( PCP ) receive long-term AZT therapy ACTG protocol 002 While treatment AZT find effective prolonging survival reduce number opportunistic infection patient AIDS , second year administration AZT acceleration mortality observe . The reason know time . The study may AZT-resistant strain HIV may benefit patient still receive AZT another drug use treat HIV ddC . It hop comparison effectiveness AZT ddC benefit treatment patient .</brief_summary>
	<brief_title>A Randomized , Unblinded Trial Zidovudine Versus ddC Treatment Patients Status Post PCP Who Received Long-Term Zidovudine Therapy Protocol ACTG 002</brief_title>
	<detailed_description>While treatment AZT find effective prolonging survival reduce number opportunistic infection patient AIDS , second year administration AZT acceleration mortality observe . The reason know time . The study may AZT-resistant strain HIV may benefit patient still receive AZT another drug use treat HIV ddC . It hop comparison effectiveness AZT ddC benefit treatment patient . Following test evaluate health , patient choose random receive either AZT ddC . AZT give mouth patient ' current dose . ddC give mouth every 8 hour . Treatment continue 12 month . Patients required visit clinic every 2 week week 12 month . Blood sample take monitor safety effectiveness treatment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<criteria>Inclusion Criteria Required : Prior zidovudine ( AZT ) therapy 9 month . Concurrent Medication : Allowed : Chemoprophylaxis Pneumocystis carinii pneumonia ( PCP ) aerosolize pentamidine 300 mg every 4 week Respirgard II nebulizer . Maintenance treatment pyrimethamine , sulfadiazine , amphotericin , fluconazole , ketoconazole , acyclovir , inhaled pentamidine subject recover toxoplasmosis , cryptococcosis , candidiasis , herpes infection , PCP . Dapsone PCP . Pyrimethaminesulfadoxine toxoplasmosis . Ganciclovir ( DHPG ) maintenance cytomegalovirus ( CMV ) retinitis . Note : Any approved medication use treat opportunistic infection . All concurrent medication keep minimum record . Patients must positive HIV ELISA test must receive zidovudine ( AZT ) therapy least 9 month receive AZT within 90 day prior entry study . Patients may transfusion dependent long 3 unit blood need 21day period hemoglobin fall 6.4 g/dl two consecutive occasion despite transfusion . Exclusion Criteria Concurrent Medication : Excluded : Antiretroviral study medication zidovudine ( AZT ) biologic response modifier . Corticosteroids chronic aspirin . Cimetidine . Flurazepam . Indomethacin . Ranitidine . Probenecid . Other experimental medication . Patients exclude study follow reason : Removal zidovudine ( AZT ) treatment ACTG protocol 002 recurrent grade 4 toxicity . Removal prior dideoxycytidine ( ddC ) therapy peripheral neuropathy = &gt; grade 3 . Visceral extensive Kaposi 's sarcoma require therapy another malignancy require therapy . Toxicity grade accord NIAID Recommendations Grading Acute Subacute Toxic Effects ( Adults ) . Prior Medication : Excluded : Antiretroviral study medication zidovudine ( AZT ) biologic response modifier . Patients may visceral extensive Kaposi 's sarcoma require therapy another malignancy require therapy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Zalcitabine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>